After peaking in mid-July, the Roundhill Magnificent Seven ETF (MAGS) corrected nearly 20% over the...

Regulatory & Political Backdrop in 2024 Bitcoin and ether have seen a rapidly improving regulatory...

The GLP-1 and weight loss drug landscape is teeming with innovation as companies test drugs with...

While the U.S. boasts the Magnificent Seven stocks – some of the dominant tech companies shaping...

Historically, emerging market equities have earned a spot in investor portfolios under the premise...

High Expectations for Earnings Season From a profit and price perspective, the Magnificent Seven...

Originally developed for diabetes treatment, the discovery of GLP-1 therapeutics as a weight loss...

On June 14, 2024, Allan Sloan published a commentary in Barron’s with the headline “There Is No...

Addressing the Obesity Epidemic The global obesity epidemic has reached alarming proportions. Since...